- Advanced search
|International Nonproprietary Names|
|Search PubMed clinical trials||nimotuzumab|
|Search PubMed titles||nimotuzumab|
|Search PubMed titles/abstracts||nimotuzumab|
|Nimotuzumab is a monoclonal antibody directed agianst the epidermal growth factor receptor (EGFR), being developed as an antineoplastic agent.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence analysis using the light chain variable region of nimotuzumab provides a 100% match with sequence 35 from patent US6506883 .
Biosimilar drug: Biocon Limited are developing BIOMAb-EGFRTM as a nimotuzumab biosimilar